安罗替尼治疗乳腺叶状肿瘤肺转移达临床完全缓解一例
A Case of Clinical Complete Response in Lung Metastasis of Breast Phyllodes Tumor Treated with Anlotinib
DOI: 10.12677/acm.2024.1492575, PDF,   
作者: 张清宇, 刘健楠:青岛大学附属烟台毓璜顶医院肿瘤内科,山东 烟台
关键词: 临床完全缓解乳腺叶状肿瘤肺转移安罗替尼Clinical Complete Response Breast Phyllodes Tumor Lung Metastasis Anlotinib
摘要: 乳腺叶状肿瘤是一种罕见的疾病,主要发生在女性中。在亚洲女性中,该病的发病年龄较早,平均发病年龄为25~30岁。乳腺叶状肿瘤(PT)可表现为远处转移,恶性PT的远处转移率可高达22%。最常见的转移部位是肺部。我们报告了一例27岁的患者,因左侧乳房出现巨大肿块就诊,该肿块在过去三个月内迅速生长。随后对左侧乳房进行了全乳切除术,病理诊断为恶性叶状肿瘤。术后一个月,患者出现肺部转移。患者拒绝了化疗,并在接受安罗替尼治疗后,肺部转移灶逐渐缩小,最终消失,显示出临床完全缓解。安罗替尼可能为恶性转移性叶状肿瘤提供一种安全有效的治疗方案。
Abstract: Breast phyllodes tumor is a rare disease that occurs in women. In Asian women, the onset of the disease occurs earlier, with an average age of 25~30 years. PT can exhibit distant metastasis, with a distant metastasis rate of up to 22% in malignant PT. The most metastases is found in the lungs. We report a case of a 27-year-old patient who presented a voluminous breast mass, rapidly growing in the past 3 months. Total mastectomy of left breast was performed thereafter, and pathology diagnosis was malignant phyllodes tumor. The patient developed lung metastasis one month after surgery. The patient refused chemotherapy and after treatment with anlotinib, the lung metastasis gradually narrowed and eventually disappeared, showing complete clinical response. Anlotinib may provide a safe and effective treatment regimen for malignant metastatic phyllodes tumor.
文章引用:张清宇, 刘健楠. 安罗替尼治疗乳腺叶状肿瘤肺转移达临床完全缓解一例[J]. 临床医学进展, 2024, 14(9): 1122-1126. https://doi.org/10.12677/acm.2024.1492575

参考文献

[1] Bernstein, L., Deapen, D. and Ross, R.K. (1993) The Descriptive Epidemiology of Malignant Cystosarcoma Phyllodes Tumors of the Breast. Cancer, 71, 3020-3024. [Google Scholar] [CrossRef
[2] Park, H., Pyo, Y.C., Kim, K.Y., Park, J.S., Shin, J., Kim, H., et al. (2018) Recurrence Rates and Characteristics of Phyllodes Tumors Diagnosed by Ultrasound-Guided Vacuum-Assisted Breast Biopsy (VABB). Anticancer Research, 38, 5481-5487. [Google Scholar] [CrossRef] [PubMed]
[3] Papas, Y., Asmar, A.E., Ghandour, F. and Hajj, I. (2019) Malignant Phyllodes Tumors of the Breast: A Comprehensive Literature Review. The Breast Journal, 26, 240-244. [Google Scholar] [CrossRef] [PubMed]
[4] Choi, N., Kim, K., Shin, K.H., Kim, Y., Moon, H., Park, W., et al. (2018) Malignant and Borderline Phyllodes Tumors of the Breast: A Multicenter Study of 362 Patients (KROG 16-08). Breast Cancer Research and Treatment, 171, 335-344. [Google Scholar] [CrossRef] [PubMed]
[5] Mituś, J., Reinfuss, M., Mituś, J.W., Jakubowicz, J., Blecharz, P., Wysocki, W.M., et al. (2014) Malignant Phyllodes Tumor of the Breast: Treatment and Prognosis. The Breast Journal, 20, 639-644. [Google Scholar] [CrossRef] [PubMed]
[6] Haldosén, L., Zhao, C. and Dahlman-Wright, K. (2014) Estrogen Receptor Beta in Breast Cancer. Molecular and Cellular Endocrinology, 382, 665-672. [Google Scholar] [CrossRef] [PubMed]
[7] Madhu Krishna, B., Chaudhary, S., Mishra, D.R., Naik, S.K., Suklabaidya, S., Adhya, A.K., et al. (2018) Estrogen Receptor Α Dependent Regulation of Estrogen Related Receptor Β and Its Role in Cell Cycle in Breast Cancer. BMC Cancer, 18, Article No. 607. [Google Scholar] [CrossRef] [PubMed]
[8] National Comprehensive Cancer Network (2021) NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 7.
[9] Wong, R.X., Koh, Y.S., Wong, F.Y., Kusumawidjaja, G., Ng, W.L., Yeo, R.M.C., et al. (2020) The Impact of Radiotherapy and Histological Risk Factors on Outcomes in Malignant Phyllodes Tumors. Clinical Breast Cancer, 20, e695-e700. [Google Scholar] [CrossRef] [PubMed]
[10] Zhang, Y. and Kleer, C.G. (2016) Phyllodes Tumor of the Breast: Histopathologic Features, Differential Diagnosis, and Molecular/Genetic Updates. Archives of Pathology & Laboratory Medicine, 140, 665-671. [Google Scholar] [CrossRef] [PubMed]
[11] Macdonald, O.K., Lee, C.M., Tward, J.D., Chappel, C.D. and Gaffney, D.K. (2006) Malignant Phyllodes Tumor of the Female Breast: Association of Primary Therapy with Cause-Specific Survival from the Surveillance, Epidemiology, and End Results (SEER) Program. Cancer, 107, 2127-2133. [Google Scholar] [CrossRef] [PubMed]
[12] Shen, G., Zheng, F., Ren, D., Du, F., Dong, Q., Wang, Z., et al. (2018) Anlotinib: A Novel Multi-Targeting Tyrosine Kinase Inhibitor in Clinical Development. Journal of Hematology & Oncology, 11, Article No. 120. [Google Scholar] [CrossRef] [PubMed]
[13] Chi, Y., Yao, Y., Wang, S., Huang, G., Cai, Q., Shang, G., et al. (2018) Anlotinib for Metastasis Soft Tissue Sarcoma: A Randomized, Double-Blind, Placebo-Controlled and Multi-Centered Clinical Trial. Journal of Clinical Oncology, 36, 11503. [Google Scholar] [CrossRef